1 Min Read
Shilpa Medicare Ltd shares rose over 6% in early trade on Tuesday, November 19, after its subsidiary secured a Certificate of Suitability (CEP) from a European drug regulator for an API used in hypertension treatment.
Shilpa Pharma Lifesciences, the company’s subsidiary, received the CEP from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for Nifedipine, according to an exchange filing.
Nifedipine, classified as a calcium-channel blocker in the dihydropyridine subclass, is used as an antihypertensive and anti-anginal medication. It reduces blood pressure and alleviates chest pain by relaxing blood vessels, enabling the heart to pump more efficiently while improving blood and oxygen supply to the heart.
Shilpa Medicare highlighted that the CEP certification reflects its capability in quality-driven development and global-standard production.
In addition, on November 18, Shilpa Pharma Lifesciences secured another CEP from EDQM for Octreotide, a synthetic peptide used to treat severe diarrhoea, acromegaly, flushing episodes in metastatic carcinoid tumours, and watery diarrhoea caused by vasoactive intestinal peptide (VIP)-secreting tumours.
Also read: Shilpa Medicare arm gets European Certificate Of Suitability for diarrhoea molecule
Shilpa Medicare shares climbed as much as 6.23% to an intraday high of ₹917.2 on the BSE on Tuesday before paring gains to trade at ₹891.70, up 3.28%, at 01:13 PM.
Shilpa Pharma Lifesciences, the company’s subsidiary, received the CEP from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for Nifedipine, according to an exchange filing.
Nifedipine, classified as a calcium-channel blocker in the dihydropyridine subclass, is used as an antihypertensive and anti-anginal medication. It reduces blood pressure and alleviates chest pain by relaxing blood vessels, enabling the heart to pump more efficiently while improving blood and oxygen supply to the heart.
Shilpa Medicare highlighted that the CEP certification reflects its capability in quality-driven development and global-standard production.
In addition, on November 18, Shilpa Pharma Lifesciences secured another CEP from EDQM for Octreotide, a synthetic peptide used to treat severe diarrhoea, acromegaly, flushing episodes in metastatic carcinoid tumours, and watery diarrhoea caused by vasoactive intestinal peptide (VIP)-secreting tumours.
Also read: Shilpa Medicare arm gets European Certificate Of Suitability for diarrhoea molecule
Shilpa Medicare shares climbed as much as 6.23% to an intraday high of ₹917.2 on the BSE on Tuesday before paring gains to trade at ₹891.70, up 3.28%, at 01:13 PM.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Live TV
Loading...